ERBB2 and breast cancer: Previous studies have also shown that in advanced breast cancer a subset of patients with HER2-negative primary tumors develop HER2-positive CTCs during disease progression [42,43], even after several months of either endocrine treatment or chemotherapy [44], which is an important part of endocrine resistance [27].